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Summary. Background: The mechanism underpinning fac-
tor XII autoactivation was originally characterized with
non-physiological surfaces, such as dextran sulfate (DS),
ellagic acid, and kaolin. Several ‘natural’ anionic activat-
ing surfaces, such as platelet polyphosphate (polyP), have
now been identified. Objective: To analyze the autoactiva-
tion of FXII by polyP of a similar length to that found in
platelets (polyP70). Methods and results: PolyP70 showed
similar efficacy to DS in stimulating autoactivation of
FXII, as detected with amidolytic substrate. Western blot-
ting revealed different forms of FXII with the two acti-
vating surfaces: two-chain aFXIIa was formed with DS,
whereas single-chain FXII (scFXII; 80 kDa) was formed
with polyP70. Dissociation of scFXII from polyP70 abro-
gated amidolytic activity, suggesting reversible exposure
of the active site. Activity of scFXII–polyP70 was
enhanced by Zn2+ and was sensitive to NaCl concentra-
tion. A bell-shaped concentration response to polyP70 was
evident, as is typical of surface-mediated reactions. Reac-
tion of scFXII–polyP70 with various concentrations of
S2302 generated a sigmoidal curve, in contrast to a hyper-
bolic curve for aFXIIa, from which a Hill coefficient of
3.67 was derived, indicative of positive cooperative bind-
ing. scFXII–polyP70 was more sensitive to inhibition by
H-D-Pro-Phe-Arg-chloromethylketone and corn trypsin
inhibitor than aFXIIa, but inhibition profiles for
C1-inhibitor were similar. Active scFXII–polyP70 was
also able to cleave its physiological targets FXI and
prekallikrein to their active forms. Conclusions: Autoacti-
vation of FXII by polyP, of the size found in platelets,
proceeds via an active single-chain intermediate. scFXII–
polyP70 shows activity towards physiological substrates,
and may represent the primary event in initiating contact
activation in vivo.
Keywords: blood coagulation; factor XII; hemostasis;
polyphosphates; zymogens.
Introduction
Activation of the contact pathway occurs upon reciprocal
proteolytic cleavage of factor XII and prekallikrein (PK)
to their active forms, FXIIa and kallikrein, in the pres-
ence of a negatively charged surface. In turn, FXIIa
cleaves FXI that is tethered to an anionic or membrane
surface, generating active FXIa. FXIa initiates a series of
ordered cleavages that feed into the prothrombinase com-
plex and ultimately generate thrombin. FXI and PK
require a non-enzymatic cofactor, high molecular weight
kininogen (HK), to facilitate binding of these proteins to
the activating surface, whereas FXII directly associates
with the surface via the fibronectin domains in the heavy
chain [1–4]. Zinc ions induce conformational changes in
FXII [5–9] and HK [10–12], enhancing the interaction of
these proteins with the anionic surface.
The function of FXII as a coagulation factor was con-
tested for many years, as a deficiency in humans is not
associated with a bleeding diathesis. It has now been
hypothesized, through the use of mouse models, that
FXII-driven coagulation is not essential for normal hemo-
stasis, but mediates pathophysiological thrombus forma-
tion [13,14]. More recently, monoclonal antibodies
(mAbs) directed against FXII have been shown to inhibit
thrombus formation in primate thrombosis models [15].
These studies have redefined the function of FXII in vivo
and highlighted it as a target for novel anticoagulant
agents that could potentially prevent nascent thrombus
growth with minimal bleeding complications. In addition
Correspondence: Nicola J. Mutch, School of Medicine & Dentistry,
Institute of Medical Sciences, Foresterhill, University of Aberdeen,
Aberdeen AB25 2ZD, UK.
Tel.: +44 1224 437492.
E-mail: n.j.mutch@abdn.ac.uk
1Now at the Department of Immunopathology, Sanquin Research
and Landsteiner Laboratory of the AMC, Amsterdam, the Nether-
lands.
Received 11 March 2014
Manuscript handled by: R. Camire
Final decision: P. H. Reitsma, 7 July 2014
© 2014 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
Journal of Thrombosis and Haemostasis, 12: 1513–1522 DOI: 10.1111/jth.12663
to its role in coagulation, FXII is likely to function in
innate immunity [16], and indeed several lines of evidence
indicate that these processes are inextricably linked [17–
19]. A second question concerning the function of FXII
in vivo was the absence of a suitable charged surface to
stimulate activation. Several potential ‘natural’ activators,
including platelet polyphosphate (polyP) [20,21], micro-
particles derived from platelets and erythrocytes [22],
RNA [23], misfolded proteins [24], collagen [25] and mast
cell heparin [26], have now been identified. PolyP is an
anionic polymer of phosphate residues that is secreted
from the dense granules of human platelets upon activa-
tion by agonists such as thrombin, ADP, and collagen
[21,27]. Platelet polyP is of a defined size of 60–100 phos-
phate units in length [21], unlike the extremely long poly-
mers found in bacteria [28]. Platelet polyP has been found
to stimulate FXII-driven procoagulant activity in vitro
[20,29] and in vivo [21] and to upregulate bradykinin-dri-
ven inflammation [21].
Binding of FXII to an anionic surface induces autoacti-
vation, via cleavage at Arg353–Val354. This generates the
active protease aFXIIa, an 80-kDa enzyme consisting of
a heavy and a light chain linked by a disulfide bond. Fur-
ther proteolytic cleavage at Arg334–Asn335 generates
bFXIIa, a solution-phase derivative largely composed of the
protease domain. bFXIIa cleaves PK, but has negligible activ-
ity towards FXI, whether surface-bound or in solution [30].
The mechanism of FXII autoactivation was characterized
prior to the identiﬁcation of physiological surfaces that were
able to support this reaction [5,31,32]. The aim of this study
was to deﬁne the ability of polyP, of similar chain length to
that found in platelets, to stimulate autoactivation of FXII
under physiological conditions. We show that autoactivation
of FXII on a ‘natural’ activating surface proceeds via an
active single-chain intermediate that is capable of cleaving
both synthetic and physiological targets.
Materials and methods
Materials
FXII, aFXIIa, FXI, PK, kallikrein, horseradish peroxidase
(HRP)-conjugated polyclonal antibody against FXII,
HRP-conjugated antibody against FXI and HRP-conju-
gated antibody against PK were from Enzyme Research
Laboratories (Swansea, UK). PolyP of average chain
length 65 (polyP65) and C1-inhibitor (C1-Inh) were from
Sigma-Aldrich (Irvine, Scotland). Dextran sulfate (DS)
with an average Mr of 500 000 and EDTA were from
Fisher Scientific (Loughborough, UK). L-Pyr-Pro-Arg-
p-nitroanilide (L-2145) and H-D-Pro-Phe-Arg-chlorometh-
ylketone (PCK) were from Bachem AG (Bubendorf,
Switzerland), and H-D-Pro-Phe-Arg-pNA-2HCl (S2302)
was from Quadratech (Epsom, UK). Corn trypsin inhibitor
(CTI) was from Haematological Technologies (Vermont,
NE, USA). NuPAGE 4–12% Bis-Tris gels, NuPAGE LDS
sample buffer, reducing agent and Mops running buffer
were from Life Technologies (Paisley, UK). Pierce spin
cups with cellulose acetate filters were from Fisher-Scienti-
fic, Loughborough, UK. Unless otherwise stated, the buffer
used throughout was 50 mM Tris-HCl (pH 7.4) and
100 mM NaCl. Polymethacrylate beads (Sepabeads EC-
HA) were a kind gift from Residion SRL (Milan, Italy).
Experiments were performed with either polyP65 or polyP70
(a kind gift from BK Giulini). Comparable results were
obtained with both preparations of polyP, which, for sim-
plicity, will be described as polyP70 throughout the article.
The concentration of polyP70 is expressed in terms of
monomer concentration throughout the article [20,33].
Chromogenic assays
FXII autoactivation FXII (50 nM) was added to 96-well
microtiter plates (Greiner, Stonehouse, UK) alone or in the
presence of either polyP70 (70 lM) or DS (1.5 lg mL
1)
with or without 10 lM ZnCl and with or without 1 mM
EDTA. This assay was performed in 50 mM Tris-HCl
(pH 7.4) buffer containing either 100 mM or 140 mM NaCl.
The chromogenic substrate S2302 (0.5 mM) was added, and
generation of activity was monitored at 405 nm every 30 s
for 2 h at 37 °C in an ELx 808 plate reader (Bio-Tek,
Potton, UK). Experiments were performed over a range of
polyP70 (0–2 mM), NaCl (0–1 M) and ZnCl2 (0–100 lM)
concentrations. A discontinuous assay for FXII autoacti-
vation was performed by incubating FXII (50 nM) alone,
with polyP70 (70 lM) or with DS (1.5 lg mL
1) at 37 °C.
At various time points (0–120 min), the reaction was
stopped by the addition of 1 M NaCl, and FXII activity
was quantified with S2302 (0.5 mM) as described above.
Gradients from the initial linear sections of absorbance vs.
time graphs were calculated and plotted against the inhibi-
tor, polyP70, NaCl or ZnCl2 concentrations with GRAPH-
PAD PRISM 5.03 (La Jolla, CA, USA). Data were analyzed
by linear regression, and accurate line-fitting was estab-
lished by analysis of residual data.
For western blot analysis of FXII autoactivation, FXII
(50 nM) was incubated alone or in the presence of 70 lM
polyP70 or 1.5 lg mL
1 DS with or without 10 lM ZnCl2
for 60 min at 37 °C. Reducing sample buffer was added,
and samples were boiled for 10 min prior to being
resolved on 4–12% NuPAGE gels and transferred to a
poly(vinylidene difluoride) membrane. FXII was detected
with a polyclonal antibody conjugated to HRP (Enzyme
Research Laboratories). A commercial preparation of
aFXIIa (50 nM) was included in the western blot as a
positive control.
FXII binding studies PolyP70 was immobilized on pri-
mary amine-containing polymethacrylate beads by the use
of 1-ethyl-3-(3-[dimethylamine]propyl) carbodiimide as
previously described [34]. FXII (2 lg) in binding buffer
(50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% bovine
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serum albumin [BSA]) was incubated with polyP70-labeled
beads or BSA-labeled (control) beads for 30 min before
centrifugation in Pierce spin cups at 1677 9 g for 30 s to
collect the flow-through. The beads were washed twice in
binding buffer before elution with a high-salt buffer
(50 mM Tris-HCl, pH 7.4, 1 M NaCl, 0.1% BSA). Sam-
ples were then separated on 4–12% gels and subjected to
western blot analysis as described above.
Single-chain FXII (scFXII)–polyP70 and aFXIIa activity
FXII (50 nM) was incubated with polyP70 (70 lM) in the
presence of increasing concentrations of S2302 substrate
(0–500 lM). The activity of aFXIIa (50 nM) was moni-
tored under comparable conditions. From the raw data,
the slope of the linear portion of the reaction was derived
with GRAPHPAD PRISM 5.03 by linear regression, and plot-
ted against the substrate concentration. The data were
then fitted to an allosteric sigmoidal model of enzyme
kinetics in the case of scFXII–polyP70, or the classic
Michaelis–Menten equation in the case of aFXIIa [35].
Inhibition studies
FXII (50 nM) in the presence of polyP70 (70 lM) or
aFXIIa (50 nM) was incubated with various concentra-
tions of CTI (0–500 nM), PCK (0–5 lM), or C1-Inh
(0–400 nM), and activity was monitored with S2302
(0.5 mM). Gradient values were derived and normalized
to activity in the absence of inhibition. Data were then
analyzed by non-linear regression (log[inhibitor] vs. nor-
malized response variable slope), allowing the IC50 values
to be determined.
FXI activation
FXI (35 nM) was incubated with or without FXII (50 nM)
and with or without polyP70 (70 lM), and activity was quan-
tified with a chromogenic substrate, L-2145. Additional
samples were removed at 100 min, and western-blotted with
an HRP-conjugated polyclonal antibody against FXI.
PK activation
PK (50 nM) was incubated with or without FXII (3 nM)
and with or without polyP70 (70 lM), and activity was
quantified with S2302. Both kallikrein and aFXIIa cleave
S2302; to control for this, the activating concentration of
FXII (3 nM) was included with or without polyP70 (70 lM).
Samples were removed at 60 min and western-blotted with
an HRP-conjugated polyclonal antibody against PK.
Data analysis
All data were analyzed with GRAPHPAD PRISM 5.03. Experi-
ments were performed in triplicate, and results are
presented as the mean  standard deviation of at least
three separate repeats. Statistical analyses were performed
with t-tests, with P < 0.05 considered to be statistically
significant.
Results
scFXII shows enzymatic activity when bound to polyP70
PolyP70 (70 lM) was found to be a potent stimulator of
FXII autoactivation, as determined in a continuous reac-
tion with a chromogenic substrate (Fig. 1A). Autoactiva-
tion of FXII was analyzed at 60 min by SDS-PAGE
under reducing conditions and western blotting with an
antibody against FXII (Fig. 1B). DS generated a two-
chain active enzyme, composed of a 50-kDa chain and a
30-kDa chain; the bands observed were of the same molec-
ular masses as those obtained with a commercial prepara-
tion of aFXIIa. In contrast, although FXII incubated
with polyP70 was capable of cleaving an amidolytic sub-
strate, it was detected as a single band at 80 kDa. We per-
formed a second chromogenic reaction under
discontinuous conditions (Fig. 1C), in which FXII
was incubated with polyP70 or DS for various times
(0–100 min). The reaction was stopped with NaCl (1 M) to
disrupt binding of FXII(a) to the activating surface. FXII
incubation with DS resulted in substantial cleavage of
S2302, but, in contrast, no FXIIa activity was detected in
preparations of FXII and polyP70. To confirm dissociation
of the scFXII–polyP70 complex by high salt concentra-
tions, we performed binding assays in which polyP70 was
directly coupled to polymethacrylate beads (Fig. 1D).
FXII was depleted in the flow-through fraction, reflective
of binding to immobilized polyP70, and was subsequently
eluted with 1 M NaCl. No binding of FXII to control
beads was observed. The transition metal ion Zn2+ is
known to enhance the association of FXII with activating
surfaces such as DS [5,36]. We analyzed the contribution
of Zn2+ to the interaction of FXII and polyP70 by per-
forming the continuous assay in the absence and presence
of 10 lM Zn2+ and 1 mM EDTA. Zn2+ dramatically
accelerated the activity generated by scFXII–polyP70, and
this effect was negated by EDTA (Fig. 1E). No significant
differences in activity were noted with EDTA alone or
when EDTA included in the reaction containing Zn2+.
The accelerated reaction in the presence of Zn2+ did not
drive formation of the of two-chain aFXIIa by polyP70, as
shown by western blotting (Fig. 1C). The activity of
scFXII–polyP70 was compromised at 140 mM NaCl, but,
interestingly, the effect of NaCl was overcome by addition
of Zn2+ (Fig. 1E). These results suggest that the two acti-
vating surfaces, polyP70 and DS, induce FXII activity by
different mechanisms. They indicate that association of
polyP70 with FXII generates an active single-chain inter-
mediate with substantial activity towards an amidolytic
substrate in the absence of proteolytic cleavage to aFXIIa.
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The optimal polyP70 polymer concentration for efficient
autoactivation of FXII was 70–140 lM (Fig. 2), as deter-
mined with the continuous assay described above. As
shown in Fig. 1E, the concentration of NaCl in the reac-
tion had a dramatic impact on autoactivation of FXII by
polyP70. We investigated this more comprehensively, and
found maximal autoactivation of FXII by polyP70 at low
NaCl concentrations (10–50 mM); however, considerable
activity was still detectable at physiological NaCl concen-
trations (Fig. 2). The strong dependence on the concen-
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Fig. 1. Activation of FXII by polyphosphate (polyP). (A) FXII (50 nM) alone or in the presence of either polyP70 (70 lM) or dextran sulfate
(DS) (1.5 lg mL1) was added to the chromogenic substrate S2302 (0.5 mM). The reaction was monitored in a plate reader at 405 nm and
37 °C. (B) FXII (50 nM) alone or in the presence of either polyP70 (70 lM) or DS (1.5 lg mL
1)  10 lM ZnCl was incubated for 60 min at
37 °C. Samples were separated on 4–12% gels alongside preformed aFXIIa (50 nM) before western blotting with an antibody against FXII. (C)
FXII (50 nM) was incubated at 37 °C for various times up to 120 min with polyP70 (70 lM), with DS (1.5 lg mL
1), or in the absence of a sur-
face. After incubation, 1 M NaCl was added before quantification of activity with S2302 (0.5 mM). (D) FXII was bound to polymethacrylate
beads labeled with polyP or bovine serum albumin (control). Starting material (SM), flow-through (FT) and high salt (HS) eluent were sepa-
rated on 4–12% gels, and detected with an antibody against FXII. (E) FXII (50 nM) alone or in the presence of 70 lM polyP70  10 lM
ZnCl  1 mM EDTA was added to 0.5 mM S2302, and the reaction was monitored as above in standard buffer containing either 100 mM or
140 mM NaCl. Data are expressed as mean  standard deviation; n = 4.
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tration of NaCl reflects the ionic nature of the interaction
between FXII and polyP70, as shown in Fig. 1D. We
found that the optimal Zn2+ concentration for enhancing
autoactivation of FXII by polyP70 was 10 lM (Fig. 2).
The presence of physiological concentrations of Zn2+
enhances the generation of scFXII–polyP70 activity and
can diminish the effect of NaCl on the reaction.
Comparison of scFXII–polyP70 activity with aFXIIa activity
We next conducted a set of experiments to investigate the
kinetics of the reaction of scFXII–polyP70 with S2302 in
comparison with a commercial preparation of aFXIIa.
aFXIIa produced a classic hyperbolic curve that, when
analyzed by use of the Michaelis–Menten equation, gave
a Km of 77 lM (Fig. 3). In contrast, a sigmoidal curve
was obtained with scFXII–polyP70 over a range of S2302
concentrations (10–400 lM) (Fig. 3), from which it was
impossible to derive a Km. The data were fitted to sigmoi-
dal substrate velocity curves (GRAPHPAD PRISM), and the
Hill coefficient determined to be 3.67, indicative of posi-
tive cooperative binding of polyP70 to FXII.
Sensitivity of scFXII–polyP70 to inhibition
We then studied inhibition of scFXII–polyP70 by a pept-
idyl inhibitor (PCK), a small protein inhibitor (CTI) and
a physiological inhibitor (C1-Inh) of FXIIa. FXII and
polyP70 (70 lM) or aFXIIa were incubated with
increasing concentrations of inhibitors (Fig. 4). Activity
was quantified with S2302 at each inhibitor concentration
tested. We found that scFXII–polyP70 was inhibited
substantially faster by CTI than the two-chain form,
aFXIIa (IC50 of 23.1  0.06 nM vs. 304.4  0.06 nM,
respectively). Similar results were obtained with PCK,
with lower IC50 values for scFXII–polyP70 than for
aFXIIa (IC50 of 533.8  0.08 nM vs. 2212  0.03 nM).
Interestingly, no difference was noted in the inhibition of
scFXII–polyP70 and aFXIIa by C1-Inh (IC50 of
113  0.1 nM vs. 104.4  0.09 nM).
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Fig. 2. Formation of single-chain FXII–polyphosphate (polyP)70. In all reactions 50 nM FXII was added to 0.5 mM S2302 in the presence of
70 lM polyP70, unless otherwise stated. The concentration of polyP70 in the reaction was varied from 0 to 2 mM. The concentration of NaCl in
the buffer was varied from 10 to 1000 mM, or ZnCl2 was included in the reaction buffer at various concentrations (0–100 lM). Results are
expressed as mean  standard deviation; n = 3.
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Fig. 3. Formation of single-chain FXII (scFXII)–polyphosphate (polyP)70 follows an allosteric mode of activation. FXII (50 nM) was incubated
with 70 lM polyP70 at various S2302 substrate concentrations (10–400 lM), and generation of activity was monitored over time. Similarly, pre-
formed aFXIIa (50 nM) was incubated with various substrate concentrations. Results are expressed as mean  standard deviation; n = 3. Data
were analyzed in GRAPHPAD PRISM with an allosteric sigmoidal model of enzyme kinetics for scFXII–polyP70 or the classic Michaelis–Menten
equation for aFXIIa; from these, the Hill coefficient and the Km were derived, respectively.
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scFXII–polyP70 cleaves physiological substrates
We tested the ability of scFXII–polyP70 to cleave its phy-
siological targets, FXI and PK. FXI with or without
FXII and with or without polyP70 (70 lM) was incubated
with a chromogenic substrate for FXI, and the activity
was quantified over a period of 2 h. Very little FXIa
activity was observed upon incubation of zymogen FXI
and FXII, but inclusion of polyP70 dramatically acceler-
ated activation (Fig. 5A). Western blotting revealed the
presence of FXIa when FXI was incubated with FXII
and polyP70 but not when it was incubated with FXII
alone. In the absence of FXII, polyP70 was unable to
directly stimulate autoactivation of FXI, consistent with
previous observations [21].
Similar experiments conducted with PK showed genera-
tion of kallikrein activity when PK was incubated with
FXII, indicating reciprocal activation of these proteases
even in the absence of an activating surface (Fig. 5B).
Inclusion of polyP70 dramatically accelerated the cleavage
of PK, and bands of kallikrein at 50 kDa and 38/35 kDa
were detected by western blotting. Interestingly, polyP70
was not efficient at stimulating PK autoactivation, but
these experiments were conducted in the absence of the
cofactor HK, which facilitates binding of PK to an acti-
vating surface. The chromogenic substrate S2302 can be
cleaved by both kallikrein and FXIIa. We therefore exam-
ined cleavage of S2302 at various FXII concentrations;
minimal cleavage of S2302 was observed until the
concentration of FXII exceeded 25 nM in the presence of
polyP70 (data not shown). These data clearly show that
scFXII–polyP70 has the capacity to cleave downstream
physiological targets in addition to amidolytic substrates.
Discussion
FXII is known to autoactivate when bound to negatively
charged surfaces. The mechanism of autoactivation has
been studied with several non-physiological surfaces,
such as DS [31,37], ellagic acid [38], and kaolin [39].
These studies provided valuable insights into the mecha-
nism underpinning FXII autoactivation, but the surfaces
were included at relatively high concentrations, and
experiments were performed at low ionic strength. In
this study, we analyzed autoactivation of FXII by the
‘natural’ surface polyP at physiological pH and ionic
strength. It has been established that longer-chain polyP,
such as those found in bacteria, are substantially more
efficient at stimulating contact activation [33]. However,
the aim of this study was to evaluate the ability of
polyP of approximately the size found in platelets to
activate FXII [21,27]. We have shown that autoactiva-
tion of FXII by polyP70 generates an active single-chain
intermediate form of FXII (scFXII), presumably by
inducing a conformational change in FXII that allows
the active site of the enzyme to open. If the interaction
of polyP70 and FXII is disrupted by high salt concentra-
tions, enzymatic activity is lost, indicating that the con-
formational change in scFXII–polyP70 is reversible.
scFXII–polyP70 is capable of cleaving synthetic and phy-
siological targets, specifically FXI and PK, to their
active forms, indicating that it may participate in biolog-
ical reactions and could provide the initial stimulus for
generating two-chain aFXIIa in vivo.
FXII is classified as a coagulation protein, but it clos-
est homolog is hepatocyte growth factor [40], and it is
also structurally analogous to the fibrinolytic proteins
tissue-type plasminogen activator (t-PA) and single-chain
urokinase plasminogen activator [41]. Interestingly, t-PA
is not considered to be a ‘true zymogen’, as it shows
catalytic activity, ~ 8% of that of the two-chain form,
as a single-chain protein (single-chain t-PA [sct-PA])
[42–44]. Fibrin functions as a cofactor for sct-PA, accel-
erating its intrinsic enzymatic activity to such a degree
that the cleaved and uncleaved forms are indistinguish-
able [45]. ‘Zymogen activation’ can therefore be
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Fig. 4. Inhibition of single-chain FXII–polyphosphate (polyP)70. FXII (50 nM) was incubated with 70 lM polyP70 (circles) in the absence or
presence of the inhibitors corn trypsin inhibitor (CTI) (0–500 nM), H-D-Pro-Phe-Arg-chloromethylketone (PCK) (0–5 lM), or C1-inhibitor
(C1-Inh) (0–400 nM). Activity was monitored with the chromogenic substrate S2302, and compared with inhibition of aFXIIa (triangles). Results
are expressed as mean  standard deviation; n = 3. Data were analyzed as described in Materials and methods to derive the IC50 values.
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achieved by direct cleavage of sct-PA by plasmin or by
binding of sct-PA to fibrin [45]. The results presented
here indicate that a similar mechanism may exist for
activation of zymogen FXII. The enzymatic activity of
aFXIIa is 4200-fold higher than that of FXII [46].
However, our data reveal that, when FXII is bound to
its ‘cofactor’, polyP70, there is a substantial increase in
enzymatic activity, roughly equivalent to that of the
same concentration of cleaved aFXIIa. The hypothesis
that FXII could show amidolytic activity in its single-
chain form was first proposed by Ratnoff and Saito
[32], after they exposed FXII to Sephadex–ellagic acid.
They found that cleavage of FXII was minimal, but
that coagulant and amidolytic properties could be
detected. This suggests that binding of FXII to a nega-
tively charged surface, at least to ellagic acid and
polyP70, is sufficient to induce a conformational change
that exposes the active site of the protein.
The FXII heavy chain contains two surface binding
regions, one in the fibronectin type I domain between
Thr134 and Arg153 [2], and one at an N-terminal site
located between Glu5 and Glu15 [1]. By use of a series of
FXII deletion mutants, an additional discontinuous
region (Pro313–Arg334, Leu334–Arg353) was identified
that can participate in surface binding [4]. Autoactivation
of FXII and cleavage by kallikrein is also enhanced by
binding of a mAb to the kringle domain of FXII, indicat-
ing that multiple mechanisms may promote FXII activa-
tion [47]. The cooperative binding kinetics observed for
FXII autoactivation by polyP70 may be explained by the
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Fig. 5. Single-chain FXII–polyphosphate (polyP)70 cleaves its physiological targets FXI and prekallikrein (PK). (A) FXI (35 nM) was incubated
alone, with FXII (50 nM), with polyP70 (70 lM) or with both in the presence of the chromogenic substrate L-2145 (0.5 mM), and the reaction
was monitored at 405 nm. Data are expressed as mean  standard deviation (SD); n = 3. Samples from the 120 min time point were separated
under reducing conditions and western-blotted with an antibody against FXI. (B) PK (50 nM) was incubated with FXII (3 nM), with polyP70
(70 lM) or with both in the presence of S2302 (0.5 mM). FXII (3 nM) with or without polyP70 (70 lM) was included as a control. Data are
expressed as mean  SD; n = 3. Samples from the 60 min time point were western-blotted with an antibody against PK.
© 2014 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
PolyP induces activity in single-chain FXII 1519
existence of multiple binding sites for anionic surfaces,
and require further studies to define the number and loca-
tion of these sites.
Generation of scFXII–polyP70 activity was dependent
on the concentration of activating surface, with an opti-
mal concentration of 70–130 lM polyP70. Higher concen-
trations of polyP70 were inhibitory, consistent with a
template mechanism of activation. Substantial amidolytic
activity was detected at low ionic strength (50 mM), but
even at physiological salt concentrations, scFXII–polyP70
showed significant activity. These observations are consis-
tent with our previous reports on polyP activation of
FXII in plasma [20,21]. Zinc ions bind to FXII, and are
known to enhance autoactivation by several surfaces,
including DS [5] and phosphatidylinositol phosphate [36].
FXII has the capacity to bind a maximum of four zinc
ions, with high affinity (0.6 lM), to a single class of inde-
pendent, non-interacting binding sites [36]. In plasma, the
concentration of Zn2+ is 5–20 lM; the majority is bound
to albumin, with only 0.25–1 lM being available as free
ion [48]. However, the concentration of Zn2+ in platelets
is 30–60-fold higher [49], and is sensitive to changes in
the extracellular concentration [50]. It has been suggested
that concentrations of ~ 10 lM free Zn2+ could be readily
achieved in the circulation following platelet activation
[51,52], and concomitant release of polyP and Zn2+ from
activated platelets may facilitate FXII activation in vivo.
In line with previous reports on autoactivation of FXII
by DS [5], our experiments indicate that, in the presence
of Zn2+, the impact of NaCl on the interaction of FXII
and polyP70 activity is diminished.
It has previously been shown that autoactivation of
FXII can be induced by low molecular mass polysaccha-
rides, but the rate is dramatically accelerated with poly-
saccharides of 10 000 Da and above [31]. The increased
level of autoactivation is explained by the existence of
multiple binding sites for FXII on larger polysaccharide
chains. In this study, we used polyP of an average chain
length of 70. By assuming a P–O bond length of 1.5 A,
we can derive the length of polyP70 as ~ 20 nm. The
diameter of FXII is 5–6 nm (Mr = 80 000), based on the
assumption that the protein molecule is approximately
spherical [31]. These calculations are approximate; how-
ever, they imply that up to four FXII molecules could
bind per chain of polyP70, which may account for the lev-
els of autoactivation and activity observed.
scFXII–polyP70 was markedly more sensitive to inhibi-
tion by CTI and PCK than two-chain aFXIIa. Interest-
ingly, there was no difference in the inhibition of
scFXII–polyP70 and aFXIIa by the serpin C1-Inh. It is
interesting to speculate on the differences in inhibition of
scFXII-polyP70 by these inhibitors, which are markedly
different in structure and mode of inhibition. It is possi-
ble that, in the case of C1-Inh, the polyanion binding
site negates the effect of polyP70, whereas with PCK a
charge interaction may occur between the arginine of the
peptide-based inhibitor PCK and polyP70, drawing it
into the active site and facilitating inhibition. CTI is a
unique inhibitor, which is relatively specific for trypsin
and FXIIa, however, like PCK the reactive site region of
CTI has a net positive charge due to an abundance of
arginine residues [53]. The positive charge associated
with the reactive sites of CTI and PCK could help to
explain the rapid inhibition of scFXII–polyP70 by these
inhibitors.
These results are the first to document the mechanism
of autoactivation of FXII by a ‘natural’ surface under
physiological conditions. Our data indicate that when
FXII is in complex with its cofactor, polyP70, it can show
enzymatic activity in the absence of proteolytic cleavage.
These data provide novel insights into the subtleties that
regulate FXII autoactivation by naturally occurring anio-
nic surfaces. It remains to be established whether binding
of other physiological activators of FXII, such as RNA
and misfolded proteins, induces similar enzymatic activity
in the single-chain form of FXII. Complex formation
between polyP released during platelet activation and
plasma FXII may provide the initiating event to stimulate
reciprocal activation of PK, subsequently leading to gen-
eration of aFXIIa by kallikrein.
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